UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Current oncology reports, 2021-08, Vol.23 (8), p.91-91, Article 91

2021

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors

Arthritis & rheumatology (Hoboken, N.J.), 2021-05, Vol.73 (5), p.866-874

2021

Link zum Volltext

Verfügbarkeit prüfen

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

American journal of hematology, 2022-05, Vol.97 (5), p.574-582

2022

Link zum Volltext

Verfügbarkeit prüfen

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials

Hematology (Luxembourg), 2023-12, Vol.28 (1), p.2254558-2254558

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors

Current oncology (Toronto), 2022-12, Vol.29 (12), p.9461-9473

2022

Link zum Volltext

Verfügbarkeit prüfen

The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia

American journal of hematology, 2020-10, Vol.95 (10), p.1127-1134

2020

Link zum Volltext

Verfügbarkeit prüfen

Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study

Clinical Medicine Insights. Oncology, 2019, Vol.13, p.1179554919835798-1179554919835798

2019

Link zum Volltext

Verfügbarkeit prüfen

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Blood, 2022-11, Vol.140 (Supplement 1), p.13285-13286

2022

Link zum Volltext

Verfügbarkeit prüfen

IBCL-015 The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S383

2022

Link zum Volltext

Verfügbarkeit prüfen

Poster: IBCL-015 The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S173

2022

Link zum Volltext

Verfügbarkeit prüfen

Representation of the population in need for pivotal clinical trials in lymphomas

Blood, 2023-08, Vol.142 (9), p.846

2023

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Blood, 2022-11, Vol.140 (Supplement 1), p.13200-13201

2022

Link zum Volltext

Verfügbarkeit prüfen

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.5274-5275

2022

Link zum Volltext

Verfügbarkeit prüfen

Are pivotal clinical trials for lymphomas that led to drug approval representative of the population affected by these diseases?

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6531-6531

2022

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Blood, 2021-11, Vol.138 (Supplement 1), p.846-846

2021

Link zum Volltext

Verfügbarkeit prüfen

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Blood, 2022-11, Vol.140 (Supplement 1), p.8929-8929

2022

Link zum Volltext

Verfügbarkeit prüfen

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3022-3022

2021

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Journal of clinical oncology, 2022-11, Vol.40 (32), p.3719-3729

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Blood, 2020-11, Vol.136 (Supplement 1), p.22-22

2020

Link zum Volltext

Verfügbarkeit prüfen

AML-468: Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single-Center, Real-World Experience

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S313-S313

2021

Link zum Volltext

Verfügbarkeit prüfen

Poster: AML-468: Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single-Center, Real-World Experience

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S210-S210

2021

Link zum Volltext

Verfügbarkeit prüfen

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Haematologica (Roma), 2021-11, Vol.106 (11), p.2853-2858

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(9)
Oncology
(9)
Hematology
(6)
Leukemia
(6)
Patients
(6)
Myeloid Leukemia
(5)
Acute Myeloid Leukemia
(4)
Female
(4)
Male
(4)
Aged
(3)
Chemotherapy
(3)
Protein-Tyrosine Kinase
(3)
Remission
(3)
Retrospective Studies
(3)
Risk Factors
(3)
Survival
(3)
Tyrosine
(3)
Antineoplastic Agents - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors

Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors

The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia

Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

IBCL-015 The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Poster: IBCL-015 The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Representation of the population in need for pivotal clinical trials in lymphomas

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Are pivotal clinical trials for lymphomas that led to drug approval representative of the population affected by these diseases?

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319)

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

AML-468: Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single-Center, Real-World Experience

Poster: AML-468: Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single-Center, Real-World Experience

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Suchergebnisse filtern